Specialty Drugs - A Distinctly American Phenomenon

N Engl J Med. 2020 Jun 4;382(23):2179-2181. doi: 10.1056/NEJMp1909513.

Authors

Huseyin Naci¹, Aaron S Kesselheim¹

Affiliation

¹ From the Department of Health Policy, London School of Economics and Political Science, London (H.N.); and the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (H.N., A.S.K.).

PMID: 32492301
DOI: 10.1056/NEJMp1909513

No abstract available

MeSH terms

Cost Sharing / economics*
Cost Sharing / legislation & jurisprudence
Cost-Benefit Analysis
Drug Costs / legislation & jurisprudence*
Drug Industry / legislation & jurisprudence*
Government Regulation
Humans
Insurance Coverage / economics
Insurance, Pharmaceutical Services / economics
Medicaid / economics
Medicare Part D / economics
Patient Protection and Affordable Care Act
Pharmaceutical Preparations / economics*
Rare Diseases / drug therapy
United States

Substances

Pharmaceutical Preparations